HomeCompareSYUP vs ARCC

SYUP vs ARCC: Dividend Comparison 2026

SYUP yields 666666.67% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYUP wins by $8.275235618773884e+34M in total portfolio value
10 years
SYUP
SYUP
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full SYUP calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — SYUP vs ARCC

📍 SYUP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYUPARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYUP + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYUP pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYUP
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, SYUP beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYUP + ARCC for your $10,000?

SYUP: 50%ARCC: 50%
100% ARCC50/50100% SYUP
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

SYUP
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYUP buys
0
ARCC buys
0
No recent congressional trades found for SYUP or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYUPARCC
Forward yield666666.67%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$8.275235618773884e+34M$24.5K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$1.14
Total dividends collected$8.275075881065991e+34M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: SYUP vs ARCC ($10,000, DRIP)

YearSYUP PortfolioSYUP Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$66,677,367$66,666,666.67$11,373$532.74+$66.67MSYUP
2$415,506,651,117$415,435,306,334.37$12,608$279.46+$415506.64MSYUP
3$2,419,908,598,386,268$2,419,464,006,269,573.00$13,809$142.90+$2419908598.37MSYUP
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$15,042$72.20+$13171697643084.44MSYUP
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$16,341$36.27+$67004927492790120.00MSYUP
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$17,732$18.18+$318562277003514871808.00MSYUP
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$19,231$9.10+$1.415484168853553e+24MSYUP
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$20,851$4.55+$5.878130573362507e+27MSYUP
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$22,605$2.28+$2.2813793009840744e+31MSYUP
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$24,504$1.14+$8.275235618773884e+34MSYUP

SYUP vs ARCC: Complete Analysis 2026

SYUPStock

Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery. It offers its products to distributors on a wholesale basis. The company is based in Shanghai, China.

Full SYUP Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this SYUP vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYUP vs SCHDSYUP vs JEPISYUP vs OSYUP vs KOSYUP vs MAINSYUP vs HTGCSYUP vs GBDCSYUP vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.